These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 7840567)

  • 1. Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections.
    Wakebe H; Imada T; Yoneda H; Mukai F; Ohguro K; Ohmori K; Tamaoka H; Yabuuchi Y
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2340-5. PubMed ID: 7840567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria.
    Wakebe H; Mitsuhashi S
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2185-91. PubMed ID: 1332589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116.
    Imada T; Miyazaki S; Nishida M; Yamaguchi K; Goto S
    Antimicrob Agents Chemother; 1992 Mar; 36(3):573-9. PubMed ID: 1320364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.
    Hosaka M; Yasue T; Fukuda H; Tomizawa H; Aoyama H; Hirai K
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2108-17. PubMed ID: 1332587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1992)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Tanimoto H; Nakata K; Nakamori Y; Nakatani T; Kusano N
    Jpn J Antibiot; 1996 Jan; 49(1):34-70. PubMed ID: 8851305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1994)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Matsuda M; Tanimoto H; Nakata K; Nakamori Y; Kusano N
    Jpn J Antibiot; 1996 May; 49(5):419-55. PubMed ID: 8752860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of OPC-17116.
    Neu HC; Fang W; Gu JW; Chin NX
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1310-5. PubMed ID: 1329620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo antibacterial activities of CS-940, a new fluoroquinolone, against isolates from patients with respiratory infections.
    Miyazaki S; Domon H; Tateda K; Ohno A; Ishii Y; Matsumoto T; Furuya N; Yamaguchi K
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2582-5. PubMed ID: 9371375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1996)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Shimizu Y; Terai T; Inoue H; Nakadate T; Ito C; Yoshida T; Ohno I; Tanno Y; Arakawa M; Igarashi K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Nakata K; Nakatani T; Inagawa H; Kusano N
    Jpn J Antibiot; 1998 Jul; 51(7):437-74. PubMed ID: 9755430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of temafloxacin against respiratory pathogens.
    Swanson RN; Hardy DJ; Chu DT; Shipkowitz NL; Clement JJ
    Antimicrob Agents Chemother; 1991 Mar; 35(3):423-9. PubMed ID: 2039192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1993)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Tanimoto H; Nakata K; Nakamori Y; Nakatani T; Kusano N
    Jpn J Antibiot; 1996 Feb; 49(2):107-43. PubMed ID: 8721076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo evaluations of A-80556, a new fluoroquinolone.
    Clement JJ; Tanaka SK; Alder J; Vojtko C; Beyer J; Hensey D; Ramer N; McDaniel D; Chu DT
    Antimicrob Agents Chemother; 1994 May; 38(5):1071-8. PubMed ID: 8067740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma bactericidal activity of a new C-5 methyl fluoroquinolone after oral doses of 400 and 800 mg.
    Gu JW; Fang W; Neu HC
    J Clin Pharmacol; 1992 Sep; 32(9):804-7. PubMed ID: 1331205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The activity of grepafloxacin against respiratory pathogens in the UK.
    Wise R; Andrews JM
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():27-30. PubMed ID: 9484870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1995)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kawaguchi H; Shimizu Y; Matsumiya H; Saito A; Terai T; Inoue H; Nakadate T; Ito C; Yosida T; Tanno Y; Ohno I; Nishioka K; Arakawa M; Igarashi K; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Touyama M
    Jpn J Antibiot; 1997 May; 50(5):421-59. PubMed ID: 9212366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1997)].
    Ikemoto H; Ito C; Yoshida T; Watanabe K; Mori T; Ohno I; Okada S; Igari J; Arakawa M; Igarashi K; Oguri T; Okada M; Ozaki K; Terai T; Aoki N; Inoue H; Nakadate T; Kitamura N; Sekine O; Suzuki Y; Ando M; Suga M; Sato K; Nakata K; Kusano N
    Jpn J Antibiot; 1999 May; 52(5):353-97. PubMed ID: 10480048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.
    Otani T; Tanaka M; Ito E; Kurosaka Y; Murakami Y; Onodera K; Akasaka T; Sato K
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3750-9. PubMed ID: 14638477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens.
    Yoshizumi S; Domon H; Miyazaki S; Yamaguchi K
    Antimicrob Agents Chemother; 1998 Apr; 42(4):785-8. PubMed ID: 9559783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of BAY Y3118, ciprofloxacin, ofloxacin, and fleroxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infections.
    Bongaerts GP; Hoogkamp-Korstanje JA
    Antimicrob Agents Chemother; 1993 Sep; 37(9):2017-9. PubMed ID: 8239624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respiratory pathogens: assessing resistance patterns in Europe and the potential role of grepafloxacin as treatment of patients with infections caused by these organisms.
    Felmingham D
    J Antimicrob Chemother; 2000 Mar; 45():1-8. PubMed ID: 10719006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.